You are here
Amgen Symposium: anemia in breast cancer – what is new?
By Xavier Pivot, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris
In his presentation, Xavier Pivot discusses anemia and fatigue. He provides an overview of the history of epoetin use which, about ten years ago, was massively prescribed as it had shown better and more regular outcomes in fighting anemia than transfusions. The improvement of haemoglobin levels reduced fatigue, the main anemia symptom, and thus improved cancer patients’ quality of life. However, problems such as thrombosis that are related to epoetin, especially at high doses, led to a decreased use. Xavier Pivot concludes that epoetin is indispensable for ensuring a good quality of life, but appropriate dosing is crucial.
Xavier Pivot, CHU, Besançon, France